The FDA has approved Intellia Therapeutics’ in vivo CRISPR medicine for hereditary angioedema (HAE), delivering regulatory clearance following a Phase 3 trial and positioning lonvoguran ziclumeran (lonvo-z) as a potential one-time treatment for patients with unpredictable, life-threatening swelling attacks. The approval follows positive Phase 3 HAELO results (NCT06634420), with the New England Journal of Medicine publication in June. The therapy is administered as an mRNA-lipid nanoparticle (LNP) that directs editing in the patient rather than requiring an ex vivo cell-manufacturing step. Regulatory review outcomes matter because current HAE drugs require ongoing dosing and can carry side effects; a durable, single-course option would change long-term management for a rare but high-burden population. Lead investigator Danny Cohn of Amsterdam University Medical Center and independent clinician Kelsey Uminski of the University of Calgary highlighted disease unpredictability as a key driver of patient impact. For the broader biotech sector, the decision further strengthens the commercial and clinical case for in vivo genome editing platforms, particularly those built on LNP delivery and mRNA expression, as regulators begin to treat them as a differentiated modality rather than a purely experimental approach.